PHARMA MAR, S.A. «...1112131415...» Página 11 de 18 desde 01/07/1988 hasta 27/09/2024 26/07/2017 18:39 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding first half 2017 results Número de registro: 255058 26/07/2017 18:32 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del primer semestre de 2017 Número de registro: 255057 26/07/2017 08:27 PHARMA MAR, S.A. Credit ratings Axesor ratifies the rating of Pharma Mar, S.A. and its outlook as stable. Número de registro: 255012 10/07/2017 12:02 PHARMA MAR, S.A. Liquidity contracts and specialists The Company announces that has entered into a liquidity agreement with Mediación Bursátil, Sociedad de Valores, S.A. Número de registro: 254397 Relacionado con 266338 del 01/06/2018 (11:07) 10/07/2017 11:14 PHARMA MAR, S.A. Liquidity contracts and specialists The Company announces the termination of the liquidity agreement entered into on May, 24, 2017 with MEDIACIÓN BURSÁTIL, SOCIEDAD DE VALORES, S.A. Número de registro: 254394 29/06/2017 14:04 PHARMA MAR, S.A. Announcements and resolutions of general shareholders meetings. - Employees share and stock ownership schemes It is reported that all proposed resolutions submitted by the Board to the General Shareholders’ Meeting have been approved. Número de registro: 254038 Relacionado con 252524 del 26/05/2017 (14:39) 29/06/2017 10:26 PHARMA MAR, S.A. Strategic plans, profit forecasts and presentations. - Announcements and resolutions of general shareholders meetings Attached is a copy of the presentation to shareholders to be made at the General Shareholders’ Meeting of Pharma Mar by the Chairman and by the Chief Financial Officer of the Company. Número de registro: 254005 01/06/2017 17:45 PHARMA MAR, S.A. Increases and decreases of share capital. - Trading: admissions, changes and removals The Company announces the admission to trading of the shares relating to the share capital increase Número de registro: 252694 29/05/2017 19:23 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks. - Announcements of public presentations and meetings Sylentis, S.A.U. has initiated the first Phase III study, HELIX, with its investigational drug SYL1001 for the treatment of dry eye syndrome Número de registro: 252585 26/05/2017 18:44 PHARMA MAR, S.A. Increases and decreases of share capital The Company announces that the public deed for the share capital increase fully subscribed and paid up by Specialised Therapeutics Investments Pty LTD ATF The Specialised Therapeutics Unit Trust, has been duly registered. Número de registro: 252547 Página 11 de 18 «...1112131415...»